Press Releases
-
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
02/08/10 -
NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
02/08/10 -
NOVAVAX Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
02/07/10 -
NOVAVAX to present at Phacilitate Vaccine Forum Washington 2010
01/25/10 -
NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
01/12/10 -
NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
12/09/09 -
NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
12/02/09 -
NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference
11/30/09 -
NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
11/30/09 -
NOVAVAX Prices Public Offering of Common Stock
11/20/09 -
NOVAVAX Announces Public Offering of Common Stock
11/20/09 -
NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico
11/16/09 -
NOVAVAX to Present at the Influenza Congress USA 2009
11/11/09 -
NOVAVAX Begins Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
11/10/09 -
NOVAVAX Reports Third Quarter 2009 Financial Results
11/06/09 -
NOVAVAX Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate in a Second Phase II Study
11/02/09 -
NOVAVAX Announces Release Date of 2009 Third Quarter Financial Results and Investor Call
10/30/09 -
NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
10/29/09 -
NOVAVAX Announces Poster Presentation at the 47th Annual Meeting of the IDSA
10/29/09 -
NOVAVAX and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
10/27/09 -
NOVAVAX to Present at 8th Annual BIO Investor Forum 2009
10/23/09 -
NOVAVAX and Xcellerex Announce Collaboration to Develop Large-scale Manufacturing Process for 2009 H1N1 Influenza VLP Vaccine
10/20/09 -
NOVAVAX Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
10/20/09 -
NOVAVAX Awarded NIH Grant For Respiratory Syncytial VIirus (RSV) Vaccine Program
10/13/09 -
Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
10/06/09 -
NOVAVAX Announces Board of Director Changes
10/01/09 -
NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
09/01/09 -
NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
08/18/09 -
NOVAVAX Reports Second Quarter 2009 Financial Results
08/07/09 -
NOVAVAX Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
08/06/09 -
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
08/05/09 -
NOVAVAX Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
07/31/09 -
NOVAVAX Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
07/22/09 -
NOVAVAX Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
07/21/09 -
NOVAVAX Announces Repayment of $5 Million of Convertible Debt
07/15/09 -
Cadila Pharmaceuticals Launches Joint Venture with Novavax in India
07/09/09